%0 Journal Article %J EMBO J %D 2001 %T Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice %A Veikkola, T %A Jussila, L %A Makinen, T %A Karpanen, T %A Jeltsch, M %A Petrova, T V %A Kubo, H %A Thurston, G %A McDonald, D M %A Achen, M G %A Stacker, S A %A Alitalo, K %X Vascular endothelial growth factor receptor-3 (VEGFR-3) has an essential role in the development of embryonic blood vessels; however, after midgestation its expression becomes restricted mainly to the developing lymphatic vessels. The VEGFR-3 ligand VEGF-C stimulates lymphangiogenesis in transgenic mice and in chick chorioallantoic membrane. As VEGF-C also binds VEGFR-2, which is expressed in lymphatic endothelia, it is not clear which receptors are responsible for the lymphangiogenic effects of VEGF-C. VEGF-D, which binds to the same receptors, has been reported to induce angiogenesis, but its lymphangiogenic potential is not known. In order to define the lymphangiogenic signalling pathway we have created transgenic mice overexpressing a VEGFR-3-specific mutant of VEGF-C (VEGF-C156S) or VEGF-D in epidermal keratinocytes under the keratin 14 promoter. Both transgenes induced the growth of lymphatic vessels in the skin, whereas the blood vessel architecture was not affected. Evidence was also obtained that these growth factors act in a paracrine manner in vivo. These results demonstrate that stimulation of the VEGFR-3 signal transduction pathway is sufficient to induce specifically lymphangiogenesis in vivo. %B EMBO J %V 20 %P 1223 - 31 %8 2001/Mar/ %G eng %U http://view.ncbi.nlm.nih.gov/pubmed/11250889 %N 6 %! The EMBO Journal %0 Journal Article %J EMBO J %D 2001 %T Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis %A Mandriota, S J %A Jussila, L %A Jeltsch, M %A Compagni, A %A Baetens, D %A Prevo, R %A Banerji, S %A Huarte, J %A Montesano, R %A Jackson, D G %A Orci, L %A Alitalo, K %A Christofori, G %A Pepper, M S %X Metastasis is a frequent and lethal complication of cancer. Vascular endothelial growth factor-C (VEGF-C) is a recently described lymphangiogenic factor. Increased expression of VEGF-C in primary tumours correlates with dissemination of tumour cells to regional lymph nodes. However, a direct role for VEGF-C in tumour lymphangiogenesis and subsequent metastasis has yet to be demonstrated. Here we report the establishment of transgenic mice in which VEGF-C expression, driven by the rat insulin promoter (Rip), is targeted to beta-cells of the endocrine pancreas. In contrast to wild-type mice, which lack peri-insular lymphatics, RipVEGF-C transgenics develop an extensive network of lymphatics around the islets of Langerhans. These mice were crossed with Rip1Tag2 mice, which develop pancreatic beta-cell tumours that are neither lymphangiogenic nor metastatic. Double-transgenic mice formed tumours surrounded by well developed lymphatics, which frequently contained tumour cell masses of beta-cell origin. These mice frequently developed pancreatic lymph node metastases. Our findings demonstrate that VEGF-C-induced lymphangiogenesis mediates tumour cell dissemination and the formation of lymph node metastases. %B EMBO J %V 20 %P 672 - 82 %8 2001/Feb/ %G eng %U http://view.ncbi.nlm.nih.gov/pubmed/11179212 %N 4 %! The EMBO Journal